MAIA Biotechnology Announces Updates In Enrollment In Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
Portfolio Pulse from Happy Mohamed
MAIA Biotechnology (NYSE:MAIA) has dosed 29 patients in its Phase 2 clinical trial, THIO-101, evaluating THIO in advanced Non-Small Cell Lung Cancer patients. The trial has rapidly increased enrollment with the addition of sites in Hungary, Poland, and Bulgaria. The company aims to treat 184 patients in the trial.
June 20, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MAIA Biotechnology's Phase 2 trial, THIO-101, has enrolled 29 patients, with rapid enrollment due to new sites in Europe. The company aims to treat 184 patients in the trial.
The rapid enrollment in MAIA Biotechnology's Phase 2 trial, THIO-101, is a positive sign for the company as it shows progress in their clinical trial. The addition of new sites in Europe will likely continue to increase enrollment, bringing the company closer to its target of 184 patients. This progress may have a positive impact on MAIA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100